NRXP Strangle Strategy
NRXP (NRx Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
NRXP (NRx Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $51.0M, a beta of 2.02 versus the broader market, a 52-week range of 1.62-3.84, average daily share volume of 903K, a public-listing history dating back to 2017, approximately 2 full-time employees. These structural characteristics shape how NRXP stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.02 indicates NRXP has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on NRXP?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current NRXP snapshot
As of May 15, 2026, spot at $3.26, ATM IV 139.00%, IV rank 25.35%, expected move 39.85%. The strangle on NRXP below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on NRXP specifically: NRXP IV at 139.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a NRXP strangle, with a market-implied 1-standard-deviation move of approximately 39.85% (roughly $1.30 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NRXP expiries trade a higher absolute premium for lower per-day decay. Position sizing on NRXP should anchor to the underlying notional of $3.26 per share and to the trader's directional view on NRXP stock.
NRXP strangle setup
The NRXP strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NRXP near $3.26, the first option leg uses a $3.42 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NRXP chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NRXP shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $3.42 | N/A |
| Buy 1 | Put | $3.10 | N/A |
NRXP strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
NRXP strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on NRXP. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on NRXP
Strangles on NRXP are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NRXP chain.
NRXP thesis for this strangle
The market-implied 1-standard-deviation range for NRXP extends from approximately $1.96 on the downside to $4.56 on the upside. A NRXP long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current NRXP IV rank near 25.35% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on NRXP at 139.00%. As a Healthcare name, NRXP options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NRXP-specific events.
NRXP strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NRXP positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NRXP alongside the broader basket even when NRXP-specific fundamentals are unchanged. Always rebuild the position from current NRXP chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on NRXP?
- A strangle on NRXP is the strangle strategy applied to NRXP (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With NRXP stock trading near $3.26, the strikes shown on this page are snapped to the nearest listed NRXP chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are NRXP strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the NRXP strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 139.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a NRXP strangle?
- The breakeven for the NRXP strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NRXP market-implied 1-standard-deviation expected move is approximately 39.85%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on NRXP?
- Strangles on NRXP are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NRXP chain.
- How does current NRXP implied volatility affect this strangle?
- NRXP ATM IV is at 139.00% with IV rank near 25.35%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.